ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

27,616Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 198

$1.38M Total Retail Price of All Prescriptions

Rank: 1 out of 198

861 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
39% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 861 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

10% of this provider’s 861 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 22,154 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 1,296 1,084 1 1
OMEPRAZOLE 1,112 897 2 3
SIMVASTATIN 887 777 3 2
LISINOPRIL 775 641 4 6
METFORMIN HCL 671 555 5 13
AMLODIPINE BESYLATE 668 627 6 4
FUROSEMIDE 640 541 7 5
POTASSIUM CHLORIDE 638 569 8 9
METOPROLOL TARTRATE 555 500 9 10
SERTRALINE HCL 524 440 10 25
WARFARIN SODIUM 523 455 11 7
HYDROCHLOROTHIAZIDE 452 416 12 16
LOSARTAN POTASSIUM 437 412 13 18
TRAMADOL HCL 434 361 14 15
GABAPENTIN 430 343 15 14
ENALAPRIL MALEATE 411 345 16 51
POLYETHYLENE GLYCOL 3350 389 250 17 41
PRAVASTATIN SODIUM 329 315 18 19
METOPROLOL SUCCINATE 327 312 19 11
HYDROCODONE-ACETAMINOPHEN 309 190 S3 20 8
ATORVASTATIN CALCIUM 291 213 21 12
ALLOPURINOL 286 269 22 23
ALENDRONATE SODIUM 275 250 23 21
ATENOLOL 271 251 24 17
ZOLPIDEM TARTRATE 270 169 25 22
GLIPIZIDE 247 195 26 62
NAMENDA 231 223 27 33
DONEPEZIL HCL 208 205 28 28
MELOXICAM 204 177 29 30
AMITRIPTYLINE HCL 200 166 R 30 69
CARVEDILOL 186 131 31 24
CARBIDOPA-LEVODOPA 178 163 32 71
GEMFIBROZIL 176 135 33 110
TAMSULOSIN HCL 170 158 34 27
QUETIAPINE FUMARATE 169 135 35 76
BUSPIRONE HCL 165 122 36 132
ESCITALOPRAM OXALATE 160 123 37 53
TRIAMCINOLONE ACETONIDE 158 136 38 143
BISOPROLOL FUMARATE 154 154 39 87
CYMBALTA 149 81 40 48
ISOSORBIDE MONONITRATE ER 143 118 41 60
LOSARTAN-HYDROCHLOROTHIAZIDE 142 122 42 49
PREDNISONE 140 118 43 29
PANTOPRAZOLE SODIUM 138 121 44 31
ACTOS 135 103 45 115
LOVASTATIN 132 131 46 70
FAMOTIDINE 131 104 47 57
MIRTAZAPINE 126 110 48 44
FLUTICASONE PROPIONATE 125 115 49 39
LEVEMIR FLEXPEN 124 95 50 149
PROPRANOLOL HCL 123 83 51 92
CRESTOR 121 99 52 26
CITALOPRAM HBR 121 91 52 20
TRAZODONE HCL 121 97 52 50
CLONIDINE HCL 121 102 52 52
ZETIA 119 74 56 68
SINGULAIR 119 70 56 106
LEVEMIR 118 97 58 140
SYMBICORT 117 89 59 150
RANITIDINE HCL 116 73 60 54
SPIRIVA 116 88 60 63
SULFAMETHOXAZOLE-TRIMETHOPRIM 115 90 62 90
PAROXETINE HCL 115 80 62 65
CLOPIDOGREL 115 87 62 42
DOXAZOSIN MESYLATE 108 96 65 96
BYSTOLIC 104 85 66 58
JANUVIA 102 78 67 86
ADVAIR DISKUS 99 90 68 47
LANTUS 98 86 69 46
TORSEMIDE 98 75 69 75
FLUOXETINE HCL 98 80 69 78
VENLAFAXINE HCL ER 97 75 72 84
LANTUS SOLOSTAR 97 73 72 85
CELEBREX 97 66 72 59
NEXIUM 94 71 75 40
LISINOPRIL-HYDROCHLOROTHIAZIDE 93 93 76 38
NASONEX 91 48 77 189
LEVOFLOXACIN 89 71 78 81
OXYBUTYNIN CHLORIDE 87 72 79 89
HYDRALAZINE HCL 86 62 80 111
ROPINIROLE HCL 83 58 81 74
GLIPIZIDE ER 83 56 81 83
BUMETANIDE 82 74 83 105
AZITHROMYCIN 82 62 83 56
DETROL LA 80 37 85 170
NAPROXEN 79 64 86 133
SPIRONOLACTONE 79 62 86 37
OXYBUTYNIN CHLORIDE ER 79 66 86 109
NIFEDIPINE ER 78 64 89 202
CIPROFLOXACIN HCL 76 66 90 55
CYCLOBENZAPRINE HCL 76 15 R 90 67
DILTIAZEM 24HR CD 75 58 92 126
VERAPAMIL ER 74 74 93 117
LIPITOR 73 43 94 116
DEXILANT 72 55 95 188
TRICOR 72 54 95 93
PLAVIX 72 60 95 66
DOXYCYCLINE HYCLATE 72 62 95 97
NYSTATIN 71 53 99 148
PEN NEEDLE 71 53 99 114
DIVALPROEX SODIUM 71 57 99 122
NOVOLOG FLEXPEN 68 43 102 174
SEROQUEL 68 59 102 168
EVISTA 67 67 104 104
LEVETIRACETAM 65 45 105 153
DIOVAN 65 58 105 34
LEXAPRO 63 48 107 204
RISPERIDONE 61 48 108 82
TRIAMTERENE-HCTZ 59 59 109 32
MONTELUKAST SODIUM 59 34 109 265
TERAZOSIN HCL 59 48 109 102
AMIODARONE HCL 58 57 112 119
BENICAR 58 58 112 100
INSULIN SYRINGE 57 32 114 95
NOVOLOG 56 36 115 107
VESICARE 56 44 115 77
BACLOFEN 56 0 115 183
PRAMIPEXOLE DIHYDROCHLORIDE 55 40 118 157
GLYBURIDE 54 53 R 119 103
LIDODERM 51 51 120 160
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 18, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.